Wongtim 1995.
Methods | Setting: Thailand, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel Intervention period: 8 weeks Masking: double blind Excluded: not stated Withdrawals: stated (none) Baseline characteristics: comparable Jadad score=3 | |
Participants | 20 adults: 10M 10F Mean (SD) age: budesonide 33.2(7.5) years, placebo 32.8(8.6) years Inclusion criteria: Mild asthma with presence of coughing or wheezing within the last 3 years 15% or greater improvement in FEV1after inhaled beta2 agonist Exclusion criteria: Use of systemic steroids, ketotifen or disodium cromoglycate within last 3 months | |
Interventions | BUD: 200 mcg 2 pfs 2xdaily (800 mcg/d) Placebo: 2 pfs 2xdaily Delivery device: Turbuhaler DPI |
|
Outcomes | Methacholine BHR (PC20 FEV1) Daily asthma symptom score Weekly beta2 agonist use Withdrawal due to asthma exacerbation | |
Notes | No reply from author to clarify details of randomisation method. Methacholine challenge data not log transformed prior to analysis | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |